Technical Analysis for GANX - Gain Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 2.72 | 1.47% | 0.04 |
GANX closed down 7.59 percent on Wednesday, May 8, 2024, on 1.68 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 10
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Lower Bollinger Band Walk | Weakness | 1.47% | |
Below Lower BB | Weakness | 1.47% | |
Lower Bollinger Band Touch | Weakness | 1.47% | |
Oversold Stochastic | Weakness | 1.47% | |
20 DMA Resistance | Bearish | -6.22% | |
1,2,3 Retracement Bearish | Bearish Swing Setup | -6.22% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -6.22% | |
Doji - Bearish? | Reversal | -6.22% | |
Doji - Bullish? | Reversal | -6.22% | |
Outside Day | Range Expansion | -6.22% |
Alert | Time |
---|---|
1.5x Volume Pace | 4 minutes ago |
Rose Above Lower Bollinger Band | 34 minutes ago |
10 DMA Resistance | 34 minutes ago |
Up 5% | 34 minutes ago |
Up 3% | 34 minutes ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/10/2024
Gain Therapeutics, Inc., a development stage biotechnology company, develops novel therapeutics to treat rare genetic and neurological disorders caused by protein misfolding in Switzerland and Spain. The company through its in-licensed proprietary Site-Directed Enzyme Enhancement Therapy platform, discovers novel allosteric sites on misfolded proteins, identifies proprietary binding sites, and restores protein folding. It has a research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Allosteric Regulation Sumitomo Group
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Allosteric Regulation Sumitomo Group
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 5.45 |
52 Week Low | 2.0 |
Average Volume | 120,598 |
200-Day Moving Average | 3.45 |
50-Day Moving Average | 3.72 |
20-Day Moving Average | 3.07 |
10-Day Moving Average | 2.93 |
Average True Range | 0.27 |
RSI (14) | 27.54 |
ADX | 30.75 |
+DI | 12.84 |
-DI | 21.11 |
Chandelier Exit (Long, 3 ATRs) | 2.85 |
Chandelier Exit (Short, 3 ATRs) | 3.45 |
Upper Bollinger Bands | 3.40 |
Lower Bollinger Band | 2.73 |
Percent B (%b) | -0.08 |
BandWidth | 21.70 |
MACD Line | -0.24 |
MACD Signal Line | -0.24 |
MACD Histogram | 0.0012 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.18 | ||||
Resistance 3 (R3) | 3.22 | 3.10 | 3.09 | ||
Resistance 2 (R2) | 3.10 | 2.97 | 3.08 | 3.06 | |
Resistance 1 (R1) | 2.89 | 2.90 | 2.83 | 2.85 | 3.04 |
Pivot Point | 2.77 | 2.77 | 2.74 | 2.75 | 2.77 |
Support 1 (S1) | 2.56 | 2.64 | 2.50 | 2.52 | 2.32 |
Support 2 (S2) | 2.44 | 2.57 | 2.42 | 2.30 | |
Support 3 (S3) | 2.23 | 2.44 | 2.27 | ||
Support 4 (S4) | 2.19 |